NCT06784648 2025-11-19
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
BioInvent International AB
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT04283890 2025-09-09
CHOPIN
Leiden University Medical Center
Phase 1/2 Active not recruiting
NCT02913417 2021-04-19
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
California Pacific Medical Center Research Institute
Phase 1/2 Unknown
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT00058279 2013-06-20
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed